The Archer® FusionPlex® Oncology Research Kit is a targeted next generation sequencing (NGS) assay to simultaneously detect and identify fusions and other mutations associated with 74 genes found in RNA transcripts that are linked to various cancers. This kit is extensive and purpose-built to advance fusion discovery, including research efforts in the area of Ph-like ALL fusions.
For Research Use Only. Not for use in diagnostic procedures.
# of GSP2s
Input nucleic acid required*
Recommended # of reads
Unique molecular on-target %
Fresh frozen or FFPE
*Input recommendations for FFPE samples vary depending on Archer Preseq® RNA QC score; 50ng input recommended in absence of PreSeq screening
ArcherDX has developed a comprehensive kit to rapidly detect translocations from total nucleic acid isolated from tumor samples, including FFPE preserved specimens. Anchored Multiplex PCR (AMP™) enrichment chemistry enables targeted amplification of fusion mRNAs, creating libraries that are optimal for multiplex NGS-based fusion detection. Archer technology permits the simultaneous detection of both known recurrent fusions as well as previously unidentified fusions at key breakpoints in target genes. The Archer FusionPlex Oncology Research Kit offers comprehensive NGS-based fusion detection, from library preparation through data analysis.
The FusionPlex Oncology Research Kit includes targets found in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), which is characterized by modifications in lymphoid transcription factor genes, poor outcomes, and a gene-expression profile similar to that of BCR-ABL1 ALL. Recent clinical and xenograft studies have revealed that the Ph-like ALL gene expression profile includes multiple genomic alterations, which are listed in the table below (table derived from ).
|Kinase Gene||Fusion Partners||5' Genes|
|ABL1||6||ETV6, NUP214, RCSD1, RANBP2, SNX2, ZMIZ1|
|PDGFRB||4||EBF1, SSBP2, TNIP1, ZEB2|
|JAK2||10||ATF7IP, BCR, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, TPR|
*FusionPlex Oncology Research Kit will only detect an EPOR truncation
The landmark discovery that gene fusions drive the development of specific cancer subtypes empowered the development of a host of targeted therapies. The exclusivity of oncogenic fusion genes to cancer cells makes them attractive targets for such therapy. Furthermore, gene fusions are also used as diagnostic and prognostic biomarkers to confirm diagnosis and monitor clinical outcome in response to therapy, respectively. The advent of next-generation sequencing greatly expedited the discovery and characterization of gene fusions in a wide variety of cancer types.
Two of the most successful cancer drugs developed to date are crizotinib and imatinib. These drugs target specific tyrosine kinases that form chimeric fusions. Crizotinib is FDA approved for ALK positive fusions in NSCLC and Imatinib induces remission in leukemia patients that are positive for BCR-ABL fusions (6).
Figure 1. Gene fusion discovery coincides with the improvement of DNA sequencing technologies. Above the timeline, the colored boxes represent the year in which the denoted gene fusion was discovered, while arrows below the timeline represent the year in which certain DNA sequencing technologies became available (graphic derived from ). The acronyms below the gene fusions represent the type of cancer with which it is associated:
2477 55th Street, Suite 202
Boulder, CO 80301